Juvenile myelomonocytic leukaemia
Conditions
Interventions
intermediate risk:azacitidine
high risk:azacitidine combined with FLAG regimen as a bridging therapy prior to HSCT and azacitidine for relapse prevention after HSC
Sponsors
Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of JMML as defined by the 2016 WHO criteria. 2. Aged <=18 years. 3. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe organ dysfunction not caused by JMML. 2. Combined with other tumors (such as solid tumors) or hematopoietic diseases. 3. Prior hematopoietic stem cell transplantation or other intravenous chemotherapy. 4. Lanskyplay performance score < 40.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| event-free survival rate;overall survival rate;Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse Rate;incidence of engraftment;incidence of acute GVHD;incidence of chronic GVHD;Transplant related mortality; | — |
Countries
China
Contacts
Public ContactChen Jing
Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed